S2P.F SIMCERE PHARMAC. GRP LTD

Healthcare Pharmaceuticals Frankfurt Exchange
1.23 EUR
Close of Nov 12, 2026
0.9883 1.53
Market cap
EUR 3.14B
P/E
17.6x
P/B
2.44x
ROE
14.3%
Dividend yield
1.90%
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is S2P.F undervalued?

Graham number
Price1.23
Graham value0.8902
Premium38.2%

S2P.F trades 38.2% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

SIMCERE PHARMAC. GRP LTD fundamental analysis

No fundamental analysis for SIMCERE PHARMAC. GRP LTD yet.

SIMCERE PHARMAC. GRP LTD stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About SIMCERE PHARMAC. GRP LTD

Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. It develops Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Leruiping, a fully human monoclonal antibody targeting IL-4Ra; Zemprocitinib a highly selective JAK1 inhibitor; and Xianlinda, an inhibitor f…

Full company profile